{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T01:30:56Z","timestamp":1793669456031,"version":"4.5.1"},"reference-count":41,"publisher":"American Society of Hematology","issue":"15","license":[{"start":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T00:00:00Z","timestamp":1717113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8,13]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Because multiple myeloma (MM) poses a formidable therapeutic challenge despite recent progress, exploring novel targets is crucial. Mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) emerges as a promising paracaspase with druggable potential, especially unexplored in MM. Our study provided compelling evidence demonstrating a statistically significant elevation of MALT1 expression in human primary MM cells. Moreover, elevated MALT1 expression was associated with a poorer prognosis in MM. Genetic deletion of MALT1 reduced cell growth, colony formation, and tumor growth in\u00a0vivo. Pharmacological inhibition with 1\u00a0\u03bcM of a small-molecular MALT1 inhibitor, Mi-2, effectively inhibited cell growth, inducing mitochondria-dependent apoptotic cell death. Mechanistically, MALT1 inhibition disrupted diverse signal transduction pathways, notably impeding nuclear factor \u03baB (NF-\u03baB). Significantly, the inhibition of MALT1 demonstrated a substantial suppression of NF-\u03baB activation by elevating inhibitor of NF-\u03baB, disrupting the nuclear localization of p65 and c-REL. This effect was observed in both the basal state and when stimulated by B-cell maturation antigen, highlighting the pivotal role of MALT1 inhibition in influencing MM cell survival. It was noteworthy that Mi-2 induces properties associated with immunogenic cell death (ICD), as evidenced by increased calreticulin, adenosine triphosphate release, and high-mobility group protein B1 upregulation, consequently triggering ICD-associated immune activation and enhancing CD8+ T-cell cytotoxicity in\u00a0vitro. In conclusion, our research highlights MALT1 as a promising druggable target for therapeutic interventions in MM, providing insights into its molecular mechanisms in MM progression.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023012394","type":"journal-article","created":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T19:37:13Z","timestamp":1717184233000},"page":"4003-4016","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":9,"title":["Halting multiple myeloma with MALT1 inhibition: suppressing BCMA-induced NF-\u03baB and inducing immunogenic cell death"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2905-6425","authenticated-orcid":false,"given":"Yao","family":"Yao","sequence":"first","affiliation":[{"name":"1Blood Disease Institute, Key Laboratory of Bone Marrow Stem Cell, Xuzhou Medical University, Xuzhou, China"},{"name":"2Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Yuan","sequence":"additional","affiliation":[{"name":"1Blood Disease Institute, Key Laboratory of Bone Marrow Stem Cell, Xuzhou Medical University, Xuzhou, China"},{"name":"2Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Shi","sequence":"additional","affiliation":[{"name":"1Blood Disease Institute, Key Laboratory of Bone Marrow Stem Cell, Xuzhou Medical University, Xuzhou, China"},{"name":"2Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Li","sequence":"additional","affiliation":[{"name":"1Blood Disease Institute, Key Laboratory of Bone Marrow Stem Cell, Xuzhou Medical University, Xuzhou, China"},{"name":"2Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqian","family":"Sha","sequence":"additional","affiliation":[{"name":"1Blood Disease Institute, Key Laboratory of Bone Marrow Stem Cell, Xuzhou Medical University, Xuzhou, China"},{"name":"2Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[{"name":"1Blood Disease Institute, Key Laboratory of Bone Marrow Stem Cell, Xuzhou Medical University, Xuzhou, China"},{"name":"2Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Canli","family":"Yuan","sequence":"additional","affiliation":[{"name":"1Blood Disease Institute, Key Laboratory of Bone Marrow Stem Cell, Xuzhou Medical University, Xuzhou, China"},{"name":"2Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Luo","sequence":"additional","affiliation":[{"name":"1Blood Disease Institute, Key Laboratory of Bone Marrow Stem Cell, Xuzhou Medical University, Xuzhou, China"},{"name":"2Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Li","sequence":"additional","affiliation":[{"name":"1Blood Disease Institute, Key Laboratory of Bone Marrow Stem Cell, Xuzhou Medical University, Xuzhou, China"},{"name":"2Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengcheng","family":"Liao","sequence":"additional","affiliation":[{"name":"3Department of Hematology\/Oncology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1375-1084","authenticated-orcid":false,"given":"Kailin","family":"Xu","sequence":"additional","affiliation":[{"name":"1Blood Disease Institute, Key Laboratory of Bone Marrow Stem Cell, Xuzhou Medical University, Xuzhou, China"},{"name":"2Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7077-6467","authenticated-orcid":false,"given":"Mingshan","family":"Niu","sequence":"additional","affiliation":[{"name":"1Blood Disease Institute, Key Laboratory of Bone Marrow Stem Cell, Xuzhou Medical University, Xuzhou, China"},{"name":"2Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,7,29]]},"reference":[{"issue":"11","key":"2024081315102760500_bib1","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2024081315102760500_bib2","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3390\/cells10020336","article-title":"Genetic abnormalities in multiple myeloma: prognostic and therapeutic implications","volume":"10","author":"Cardona-Benavides","year":"2021","journal-title":"Cells"},{"issue":"11","key":"2024081315102760500_bib3","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1182\/blood.V93.11.3601","article-title":"The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas","volume":"93","author":"Dierlamm","year":"1999","journal-title":"Blood"},{"issue":"42","key":"2024081315102760500_bib4","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.1038\/sj.onc.1203018","article-title":"A\u00a0novel gene, MALT1 at 18q21, is involved in t(11;18) (q21;q21) found in low-grade B-cell lymphoma of mucosa-associated lymphoid tissue","volume":"18","author":"Akagi","year":"1999","journal-title":"Oncogene"},{"issue":"17","key":"2024081315102760500_bib5","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1111\/febs.13325","article-title":"MALT1--a universal soldier: multiple strategies to ensure NF-kappaB activation and target gene expression","volume":"282","author":"Afonina","year":"2015","journal-title":"FEBS J"},{"issue":"4","key":"2024081315102760500_bib6","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.celrep.2014.10.044","article-title":"Uncoupling Malt1 threshold function from paracaspase activity results in destructive autoimmune inflammation","volume":"9","author":"Gewies","year":"2014","journal-title":"Cell Rep"},{"issue":"47","key":"2024081315102760500_bib7","doi-asserted-by":"crossref","first-page":"19946","DOI":"10.1073\/pnas.0907511106","article-title":"Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma","volume":"106","author":"Hailfinger","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"22","key":"2024081315102760500_bib8","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1038\/sj.emboj.7601897","article-title":"Malt1 ubiquitination triggers NF-kappaB signaling upon T-cell activation","volume":"26","author":"Oeckinghaus","year":"2007","journal-title":"EMBO J"},{"issue":"3","key":"2024081315102760500_bib9","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/leu.2016.239","article-title":"A\u00a0role for MALT1 activity in Kaposi's sarcoma-associated herpes virus latency and growth of primary effusion lymphoma","volume":"31","author":"Bonsignore","year":"2017","journal-title":"Leukemia"},{"issue":"3","key":"2024081315102760500_bib10","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/ni1561","article-title":"T\u00a0cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kappaB inhibitor A20","volume":"9","author":"Coornaert","year":"2008","journal-title":"Nat Immunol"},{"issue":"35","key":"2024081315102760500_bib11","doi-asserted-by":"crossref","first-page":"14596","DOI":"10.1073\/pnas.1105020108","article-title":"Malt1-dependent RelB cleavage promotes canonical NF-kappaB activation in lymphocytes and lymphoma cell lines","volume":"108","author":"Hailfinger","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2024081315102760500_bib12","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41408-023-00809-7","article-title":"MALT1-dependent cleavage of CYLD promotes NF-kappaB signaling and growth of aggressive B-cell receptor-dependent lymphomas","volume":"13","author":"Minderman","year":"2023","journal-title":"Blood Cancer J"},{"issue":"8","key":"2024081315102760500_bib13","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1111\/febs.16699","article-title":"Normal lymphocyte homeostasis and function in MALT1 protease-resistant HOIL-1 knock-in mice","volume":"290","author":"Skordos","year":"2023","journal-title":"FEBS J"},{"issue":"4","key":"2024081315102760500_bib14","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1177\/0022034515621740","article-title":"MALT1 inhibition of oral carcinoma cell invasion and ERK\/MAPK activation","volume":"95","author":"Chiba","year":"2016","journal-title":"J\u00a0Dent Res"},{"issue":"7","key":"2024081315102760500_bib15","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/onc.2015.146","article-title":"MALT1 is required for EGFR-induced NF-kappaB activation and contributes to EGFR-driven lung cancer progression","volume":"35","author":"Pan","year":"2016","journal-title":"Oncogene"},{"issue":"2","key":"2024081315102760500_bib16","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41577-018-0087-2","article-title":"CARD-BCL-10-MALT1 signalling in protective and pathological immunity","volume":"19","author":"Ruland","year":"2019","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"2024081315102760500_bib17","first-page":"961","article-title":"Identification of paracaspases and metacaspases: two ancient families of caspase-like proteins, one of which plays a key role in MALT lymphoma","volume":"6","author":"Uren","year":"2000","journal-title":"Mol Cell"},{"key":"2024081315102760500_bib18","doi-asserted-by":"crossref","first-page":"558339","DOI":"10.3389\/fonc.2020.558339","article-title":"MALT1 inhibition as a therapeutic strategy in T-cell acute lymphoblastic leukemia by blocking notch1-induced NF-kappaB activation","volume":"10","author":"Wang","year":"2020","journal-title":"Front Oncol"},{"issue":"3","key":"2024081315102760500_bib19","first-page":"301","article-title":"Unraveling the biology of multiple myeloma disease: cancer stem cells, acquired intracellular changes and interactions with the surrounding micro-environment","volume":"95","author":"Caers","year":"2008","journal-title":"Bull Cancer"},{"issue":"37","key":"2024081315102760500_bib20","doi-asserted-by":"crossref","first-page":"5673","DOI":"10.1038\/sj.onc.1205664","article-title":"Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1\/Akt signaling in human multiple myeloma cells: therapeutic implications","volume":"21","author":"Mitsiades","year":"2002","journal-title":"Oncogene"},{"issue":"19","key":"2024081315102760500_bib21","doi-asserted-by":"crossref","first-page":"5903","DOI":"10.1158\/1078-0432.CCR-07-0753","article-title":"Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model","volume":"13","author":"Neri","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2024081315102760500_bib22","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1182\/blood-2003-06-2043","article-title":"Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival","volume":"103","author":"Novak","year":"2004","journal-title":"Blood"},{"issue":"12","key":"2024081315102760500_bib23","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1128\/MCB.21.12.4067-4074.2001","article-title":"B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses","volume":"21","author":"Xu","year":"2001","journal-title":"Mol Cell Biol"},{"issue":"1","key":"2024081315102760500_bib24","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1084\/jem.20031330","article-title":"BCMA is essential for the survival of long-lived bone marrow plasma cells","volume":"199","author":"O'Connor","year":"2004","journal-title":"J\u00a0Exp Med"},{"issue":"13","key":"2024081315102760500_bib25","doi-asserted-by":"crossref","first-page":"7550","DOI":"10.1111\/jcmm.15383","article-title":"MALT1 is a potential therapeutic target in glioblastoma and plays a crucial role in EGFR-induced NF-kappaB activation","volume":"24","author":"Liu","year":"2020","journal-title":"J\u00a0Cell Mol Med"},{"issue":"5","key":"2024081315102760500_bib26","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1158\/0008-5472.CAN-17-1089","article-title":"The CARMA3-Bcl10-MALT1 signalosome drives NFkappaB activation and promotes aggressiveness in angiotensin II receptor-positive breast cancer","volume":"78","author":"Ekambaram","year":"2018","journal-title":"Cancer Res"},{"issue":"49","key":"2024081315102760500_bib27","doi-asserted-by":"crossref","first-page":"7384","DOI":"10.1038\/s41388-019-0958-4","article-title":"MALT1 is a critical mediator of PAR1-driven NF-kappaB activation and metastasis in multiple tumor types","volume":"38","author":"McAuley","year":"2019","journal-title":"Oncogene"},{"issue":"8","key":"2024081315102760500_bib28","first-page":"e988042","article-title":"Autocrine signaling of type 1 interferons in successful anticancer chemotherapy","volume":"4","author":"Vacchelli","year":"2015","journal-title":"Oncoimmunology"},{"issue":"11","key":"2024081315102760500_bib29","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/nm.3708","article-title":"Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy","volume":"20","author":"Sistigu","year":"2014","journal-title":"Nat Med"},{"issue":"5","key":"2024081315102760500_bib30","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1158\/2643-3230.BCD-21-0047","article-title":"Bortezomib induces anti-multiple myeloma immune response mediated by cGAS\/STING pathway activation","volume":"2","author":"Gulla","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"10","key":"2024081315102760500_bib31","doi-asserted-by":"crossref","first-page":"e005442","DOI":"10.1136\/jitc-2022-005442","article-title":"Combining precision oncology and immunotherapy by targeting the MALT1 protease","volume":"10","author":"Mempel","year":"2022","journal-title":"J\u00a0Immunother Cancer"},{"issue":"1","key":"2024081315102760500_bib32","doi-asserted-by":"crossref","first-page":"59","DOI":"10.18632\/oncotarget.109","article-title":"A\u00a0critical role for the NFkB pathway in multiple myeloma","volume":"1","author":"Demchenko","year":"2010","journal-title":"Oncotarget"},{"issue":"25","key":"2024081315102760500_bib33","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","article-title":"APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment","volume":"127","author":"Tai","year":"2016","journal-title":"Blood"},{"issue":"7","key":"2024081315102760500_bib34","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/sj.bjc.6605241","article-title":"Atacicept in relapsed\/refractory multiple myeloma or active Waldenstrom's macroglobulinemia: a phase I study","volume":"101","author":"Rossi","year":"2009","journal-title":"Br J Cancer"},{"issue":"3","key":"2024081315102760500_bib35","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1182\/blood-2004-11-4512","article-title":"The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature","volume":"106","author":"Moreaux","year":"2005","journal-title":"Blood"},{"issue":"9","key":"2024081315102760500_bib36","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1038\/leu.2015.68","article-title":"Myelopoiesis dysregulation associated to sustained APRIL production in multiple myeloma-infiltrated bone marrow","volume":"29","author":"Matthes","year":"2015","journal-title":"Leukemia"},{"issue":"6","key":"2024081315102760500_bib37","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","article-title":"Immunological effects of conventional chemotherapy and targeted anticancer agents","volume":"28","author":"Galluzzi","year":"2015","journal-title":"Cancer Cell"},{"issue":"6102","key":"2024081315102760500_bib38","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1126\/science.1224922","article-title":"An immunosurveillance mechanism controls cancer cell ploidy","volume":"337","author":"Senovilla","year":"2012","journal-title":"Science"},{"issue":"91","key":"2024081315102760500_bib39","doi-asserted-by":"crossref","first-page":"12087","DOI":"10.1039\/D1CC04604G","article-title":"Immunogenic cell death inducers for enhanced cancer immunotherapy","volume":"57","author":"Li","year":"2021","journal-title":"Chem Commun (Camb)"},{"issue":"6","key":"2024081315102760500_bib40","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1182\/blood.2019004713","article-title":"Identification of MALT1 feedback mechanisms enables rational design of potent antilymphoma regimens for ABC-DLBCL","volume":"137","author":"Fontan","year":"2021","journal-title":"Blood"},{"issue":"51","key":"2024081315102760500_bib41","doi-asserted-by":"crossref","first-page":"39128","DOI":"10.1074\/jbc.M610023200","article-title":"Dexamethasone represses signaling through the mammalian target of rapamycin in muscle cells by enhancing expression of REDD1","volume":"281","author":"Wang","year":"2006","journal-title":"J\u00a0Biol Chem"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/15\/4003\/2237898\/blooda_adv-2023-012394-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/15\/4003\/2237898\/blooda_adv-2023-012394-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T15:17:36Z","timestamp":1723562256000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/15\/4003\/516340\/Halting-multiple-myeloma-with-MALT1-inhibition"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,29]]},"references-count":41,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2024,8,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023012394","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,29]]}}}